Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-01 · 1879 (1) · 189033
DOI: 10.1016/j.bbcan.2023.189033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-01. Verfasst von Shenglong Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Second ward of Bone and Soft Tissue Tumor Surgery,Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Li…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Bone Neoplasms. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 153 Literaturangaben. Gefördert von: Dalian University of Technology, Liaoning Cancer Hospital and Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Despite standard hormonal therapy that targets the androgen receptor (AR) attenuates prostate cancer (PCa) effectively in the initial stage, the tumor ultimately converts to castration-resistant prostate cancer (CRPC), and the acquired resistance is still a great challenge for the management of advanced prostate cancer patients. The tumor microenvironment (TME) consists of multiple cellular and noncellular agents is well known as a vital role during the development and progression of CRPC by establishing communication between TME and tumor cells. Additionally, as primary prostate cancer progresses towards metastasis, and CRPC always experiences bone metastasis, the TME is conducive to the spread of tumors to the distant sits, particularly in bone. In addition, the bone microenvironment (BME) is also closely related to the survival, growth and colonization of metastatic tumor cells. The present review summarized the recent studies which mainly focused on the role of TME or BME in the CRPC patients with bone metastasis, and discussed the underlying mechanisms, as well as the potential therapeutic values of targeting TME and BME in the management of metastatic CRPC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second ward of Bone and Soft Tissue Tumor Surgery,Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China; The Liaoning Prov…
- Department of Breast Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.
- Department of Urology, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China. Electronic address: zengyud07@foxmail.com.
Förderung
- Dalian University of Technology
- Liaoning Cancer Hospital and Institute
Zitieren
APA
Li, S., Kang, Y., & Zeng, Y. (2024). Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(1), 189033. https://doi.org/10.1016/j.bbcan.2023.189033
Vancouver
Li S, Kang Y, Zeng Y. Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(1):189033. doi:10.1016/j.bbcan.2023.189033
BibTeX
@article{Li2024,
author = {Li, Shenglong and Kang, Yue and Zeng, Yu},
title = {Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {1},
pages = {189033},
doi = {10.1016/j.bbcan.2023.189033}
}
EUVIMED